Under the research collaboration, serum and urine samples collected by Hirosaki investigators from well-characterized patient and control populations in Japan, will be examined.
The glycan analysis will be conducted by Ezose leveraging its GlycanMap technology platform at its US laboratories.
Ezose R&D vice president Hidehisa Asada said, "Given the already established clinical utility of glycan-based biomarkers in certain cancers, we believe that further studies in oncology hold promise for identifying other novel biomarkers that could help guide clinical practice."
As a part of the agreement, Ezose received exclusive rights from Hirosaki to develop and commercialize new biomarkers resulting from the collaboration.